tHEORetically Speaking

HealthEconomics.com
  • 0,0 (0)
  • БИОНАУКИ
  • ДВАЖДЫ В НЕДЕЛЮ

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

  1. INsights & OUTcomes with Mark Larkin

    20 АПР.

    INsights & OUTcomes with Mark Larkin

    On this episode of INsights & OUTcomes, we sit down with Mark Larkin, real-world evidence expert at Vitaccess, to explore why the "gold standard" of clinical trials often falls short the moment a treatment hits the real world. We dive deep into the shift toward patient-centered science, discussing the critical difference between a study that is truly patient-centric versus one that is merely "patient-advised." Mark explains how longitudinal data is filling the gaps left by RCTs, from capturing the granular daily impacts of rare diseases to understanding the ripple effect of treatments on caregivers. Watch the full conversation here: https://youtu.be/ApKzubFy4Ao

    29 мин.
  2. Weekly News Roundup — PhRMA Leadership Transition, The ICHRA Shift, and MDUFA VI Preliminary Deal

    10 АПР.

    Weekly News Roundup — PhRMA Leadership Transition, The ICHRA Shift, and MDUFA VI Preliminary Deal

    This week’s tHEORetically Speaking News Roundup covers Steve Ubl’s planned departure from PhRMA after a decade of navigating the industry through landmark legislative shifts, and the growing momentum of ICHRAs as employers move toward "defined contribution" healthcare models. We also break down the preliminary MDUFA VI agreement, which signals a major hiring push at the FDA and a new "America-First" fee structure for medtech.  Tune in for this concise recap of these pivotal industry updates!

    4 мин.
  3. Weekly News Roundup — Medtech Mega Deals, EU Regulatory Delays, and Global Supply Chain Shock

    27 МАР. ·  БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — Medtech Mega Deals, EU Regulatory Delays, and Global Supply Chain Shock

    This week’s tHEORetically Speaking News Roundup covers Abbott’s $21 billion acquisition of Exact Sciences, signaling a major expansion in cancer diagnostics, and Boehringer Ingelheim’s concerns over Europe’s slowing regulatory timelines compared to the U.S. We also break down a global supply chain shock triggered by the Strait of Hormuz closure.  Tune in for this concise recap of these pivotal industry updates!

    3 мин.
  4. Weekly News Roundup — Medicaid Maternal Care Expansion, Breakthrough Diabetes Data, and SMA Market Shakeups

    20 МАР. ·  БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — Medicaid Maternal Care Expansion, Breakthrough Diabetes Data, and SMA Market Shakeups

    This week’s tHEORetically Speaking News Roundup covers Nadia Care’s $12M raise to expand Medicaid-focused maternal care, Eli Lilly’s breakthrough Phase 3 results for its triple agonist retatrutide in type 2 diabetes, and Roche’s decision to halt development of its SMA therapy—reshaping competition in the rare disease space. Tune in for this concise recap of the key developments shaping the HEOR, RWE, and market access landscape.

    3 мин.
  5. Weekly News Roundup — Biosimilar Policy Changes, mRNA Leadership Shifts, and Rare Disease Market Growth

    13 МАР. ·  БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — Biosimilar Policy Changes, mRNA Leadership Shifts, and Rare Disease Market Growth

    This week’s tHEORetically Speaking News Roundup covers the FDA’s new guidance aimed at streamlining biosimilar development and reducing drug costs, leadership changes at BioNTech as its founders step down to launch a new mRNA venture, and projections that the global rare disease drug market could surpass $400 billion by 2032. We also explore the FDA’s launch of a new unified adverse event monitoring platform designed to modernize safety surveillance and improve transparency.  Tune in for this concise recap of the key developments shaping the life sciences, HEOR, and market access landscape.

    4 мин.
  6. Weekly News Roundup — mRNA Vaccine Milestones, Obesity Drug Manufacturing, and Gene Therapy Regulatory Tensions

    6 МАР. ·  БОНУСНЫЙ КОНТЕНТ

    Weekly News Roundup — mRNA Vaccine Milestones, Obesity Drug Manufacturing, and Gene Therapy Regulatory Tensions

    This week’s tHEORetically Speaking News Roundup covers Moderna’s progress toward European approval of its combination COVID-19 and flu mRNA vaccine, Novo Nordisk’s $501 million investment to expand Wegovy pill production in Ireland, and Moderna’s $2.25 billion settlement resolving a major mRNA patent dispute. We also explore the FDA’s disagreement with uniQure over clinical trial requirements for its Huntington’s gene therapy.  Tune in for this concise recap of the key developments shaping the life sciences and market access landscape.

    4 мин.
  7. INsights & OUTcomes with Radek Wasiak

    27 ФЕВР.

    INsights & OUTcomes with Radek Wasiak

    This episode features Radek Wasiak, an expert in real world data generation, and real-world evidence. He has provided research services to the life sciences for more than two decades and is currently the director of Adigens Health. This chat wasn't just a technical deep dive; it was a journey through the past, present, and future of how we prove medicine actually works, and highlights the high-stakes world of Real-World Evidence (RWE). To watch the full interview, click here! Learn more about Adigens Health: https://www.adigenshealth.com/ Adigens Health partners with life sciences companies to harness insights and real-world evidence to expedite clinical development and effectively prepare for asset launch.

    26 мин.
  8. Integrated Evidence Delivery: Why HEOR belongs at the heart of the Modern CRO

    23 ФЕВР.

    Integrated Evidence Delivery: Why HEOR belongs at the heart of the Modern CRO

    In this episode, we explore why the traditional 'clinical-first, value-later' model is becoming a strategic liability and why integrating HEOR into CRO operations is the new industry standard. Join us as Aaron Berger and Dr. Mir Sohail Fazeli break down how to eliminate vendor silos to build a seamless, lifecycle-wide evidence narrative that ensures regulatory success. To learn more about this, check out the deep-dive blog here: https://healtheconomics.com/integrated-evidence-delivery-the-strategic-role-of-heor-in-modern-cros

    32 мин.
См. все (84)

Об этом подкасте

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

Информация

  • Автор
    HealthEconomics.com
  • Годы выхода
    2022 - 2026
  • Выпуски
    84
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2026 tHEORetically Speaking
  • Сайт подкаста
    tHEORetically Speaking